In addition, to investigate the co‐expression of these genes in clinical samples, we cross‐checked the mRNA levels of PRSS3, PAR2, and FOSL1 in lung cancer datasets using cBioPortal.[45, 46, 47] The regression analysis performed by cBioPortal showed that there were positive correlations between the mRNA levels of PRSS3 versus PAR2, PRSS3 versus FOSL1, PAR2 versus FOSL1 in 230 cancer patients with lung adenocarcinoma and in 484 cancer patients with lung squamous cell carcinoma (Figure S9A,B, Supporting Information). This evidence concerns the gene PRSS3 and cancer.